Amneal Pharmaceuticals

Amneal Pharmaceuticals, Inc. is a pharmaceutical company, which engages in the development, manufacture, market and distribution of generic pharmaceutical products. It operates through the Generic, Specialty and AvKARE Segments. The Generics segment develops, manufactures and commercializes complex oral solids, injectables, ophthalmics, liquids, topicals, softgels, inhalation products and transdermals. The Specialty segment provides proprietary medicines to the U.S. market. The AvKARE segment focuses on pharmaceuticals, medical and surgical products, and services primarily to governmental agencies. The company was founded by Chintu Patel and Chirag Patel in 2002 and is headquartered in Bridgewater, NJ.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Amneal Pharmaceuticals reports strong Q4 earnings and outlines growth strategies

Amneal Pharmaceuticals delivered strong Q4 2022 results with revenue of $610 million and adjusted EBITDA of $154 million, expecting stable performance in 2023 with total revenue of $2.25-2.35 billion.
The company's strategic focus on complex, high-growth products, international expansion, and new product launches positions it for growth opportunities despite challenges in generic growth rates and competitive pressures.
With a robust biosimilars growth plan, unique pricing strategies, and market expansion initiatives, Amneal Pharmaceuticals aims to capture market share, drive revenue growth, and sustain its performance in the pharmaceutical industry.
Despite facing challenges such as potential competition and manufacturing delays, Amneal Pharmaceuticals remains optimistic about its growth prospects, emphasizing long-term strategies for revenue expansion and market positioning.

Amneal Pharmaceuticals reports strong Q1 results and eyes strategic growth

Amneal Pharmaceuticals' Q1 2023 performance reflects strategic growth initiatives across all segments, positioning the company for future success.
While challenges like debt reduction and refinancing exist, the company's strengths in product diversification and market adoption offer growth potential.
Opportunities in Injectables, Biosimilars, and capital allocation strategies provide avenues for revenue growth and operational excellence.

Amneal Pharmaceuticals reports strong Q2 earnings, eyes sustainable growth

Amneal Pharmaceuticals is on track for sustainable growth and EBITDA acceleration.
The company is well-positioned to capitalize on the growth potential in biosimilars and complex generics.
With a focus on organic growth and new product launches, Amneal aims to drive revenue and expand market share.

Amneal Pharmaceuticals excels in Q3, eyes international expansion and specialty growth

Amneal Pharmaceuticals reported strong financials, raised guidance, and highlighted growth in key segments. The company's strategic focus on operational efficiency, supply chain expansion, and international growth positions it for sustained success. Challenges include managing expenses and liabilities, but opportunities in new markets and product segments offer avenues for growth.

Amneal Pharmaceuticals posts record revenue in Q4 2023, eyes biosimilar growth

Amneal Pharmaceuticals reported robust financials for Q4 2023 and full-year 2023, with record revenue and EBITDA figures. The company's strategic focus on biosimilars, portfolio expansion, and growth initiatives underpin its optimistic outlook for 2024. Despite industry challenges, Amneal remains committed to innovation, affordability, and addressing pricing issues.

Amneal Pharmaceuticals reports record Q1 revenues and eyes biosimilar growth

Amneal Pharmaceuticals' Q1 performance reflects robust growth across all segments, underpinned by strong financial execution and a sustainable growth profile.
The company's strengths lie in its market position, diverse portfolio, commitment to quality, and strategic partnerships, positioning them for continued success.
While facing challenges related to product approvals and revenue uncertainties, Amneal is well-positioned to capitalize on opportunities in biosimilars, strategic partnerships, and market expansion.

Amneal Pharmaceuticals excels in Q2, eyes international expansion for growth

Amneal Pharmaceuticals delivered a strong performance in Q2 2024, with robust revenue growth and raised guidance, signaling confidence in future prospects.
The company's strategic strengths lie in international expansion, diversified revenue streams, and a focus on financial stability through debt reduction and investments.
Challenges include maintaining growth momentum, effective execution of expansion plans, and balancing debt reduction with growth investments.
Opportunities abound in new product approvals, market expansion, and innovation, positioning Amneal Pharmaceuticals for sustained growth and market leadership.

Amneal Pharmaceuticals reports robust Q3 results and eyes future growth

Amneal Pharmaceuticals' Q3 performance reflects strong revenue growth and strategic product initiatives in key therapeutic areas.
The company's focus on affordable medicines, biosimilars, and strategic investments underscores its commitment to future growth.
While facing challenges in market competition and operational optimization, Amneal is well-positioned to leverage growth opportunities.
With a solid financial performance and a focus on sustainable value creation, Amneal is poised for long-term success in the pharmaceutical industry.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Amneal Pharmaceuticals, Inc. is a medicine company, which engages in the provision of pharmaceuticals. Its product portfolio includes generics, specialty, biosciences, and product catalog. It operates through the following segments: Generics, Specialty, and AvKARE. The Generics segment relates to oral solids, powders, liquids, sterile injectables, nasal sprays, inhalation and respiratory products, biosimilar products, ophthalmics, films, and transdermal patches and topicals. The Specialty segment refers to the development, promotion, sale, and distribution of proprietary branded pharmaceutical products. The AvKARE segment provides pharmaceuticals, medical, and surgical products and services to governmental agencies. The company was founded by Chirag K. Patel and Chintu Patel in 2002 and is headquartered in Bridgewater, NJ.

BRIDGEWATER, N.J.--(BUSINESS WIRE)--Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (“Amneal” or the “Company”) announced that it has received approval of an additional strength of 500 mg to its Abbreviated New Drug Application (ANDA), from the U.S. Food and Drug Administration (FDA) for Abiraterone Acetate Tablets, USP, 250 mg and 500 mg. This ANDA is approved for its use in combination with Prednisone. Abiraterone Acetate Tablets, USP, 250 mg and 500 mg, are the generic version of Zytiga® for treat

Amneal Launches Generic Abiraterone Acetate Tablets, USP, 500 mg, Following ANDA Approval by FDA

BRIDGEWATER, N.J.--(BUSINESS WIRE)--Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (the “Company”) today announced that Chirag Patel, Amneal's Co-Chief Executive Officer and President, will present at the 39th Annual J.P. Morgan Healthcare Conference on January 13, 2021 at 2:50 PM Eastern Time. A live webcast of the presentation will be accessible through the Investor Relations section of the Company's website at https://investors.amneal.com. A replay of the webcast will be posted shortly after the

Amneal to Virtually Participate at the 39th Annual J.P. Morgan Healthcare Conference

As part of its outlook for biopharma companies in 2021, Guggenheim Securities turned bullish on Amneal Pharmaceuticals Inc (NYSE: AMRX). The Amneal Analyst: Dana Flanders upgraded Amneal from Neutral to Buy with a $5.50 price target.

Amneal Analyst: Pharma Well-Positioned Ahead Of 2021 Generic Launches

Amphastar Pharma

Biogen

Horizon Pharma

Phibro Animal Health

Supernus Pharmaceuticals

These are the pharmaceutical stocks with the best value, fastest growth, and most momentum for Q1 2021.

Top Pharmaceutical Stocks for Q1 2021

Is Amneal Pharmaceuticals (AMRX) a great pick from the value investor's perspective right now? Read on to know more.

Is Amneal Pharmaceuticals (AMRX) a Good Stock to Pick Now?

BRIDGEWATER, N.J.--(BUSINESS WIRE)--Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (“Amneal”) today announced that it has received approval for its Abbreviated New Drug Application (ANDA) from the U.S. Food and Drug Administration (FDA) for Acyclovir Cream, 5%. Acyclovir Cream, 5%, is the generic version of Zovirax® for treatment of recurrent herpes labialis (cold sores) in immunocompetent adults and adolescents 12 years of age and older. The product is available by prescription only and is associat

Amneal Receives Abbreviated New Drug Application Approval for Acyclovir Cream, 5%

Amneal Pharmaceuticals, Inc. (AMRX) CEO Chintu Patel on Q3 2020 Results - Earnings Call Transcript

Shares of Amneal Pharmaceuticals (NYSE:AMRX) rose 1.0% in pre-market trading after the company reported Q3 results.

Recap: Amneal Pharmaceuticals Q3 Earnings

Amneal (AMRX) delivered earnings and revenue surprises of 23.08% and 8.13%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?

Amneal Pharmaceuticals (AMRX) Q3 Earnings and Revenues Top Estimates

BRIDGEWATER, N.J.--(BUSINESS WIRE)--Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (the “Company”) announced its results today for the third quarter ended September 30, 2020. “Amneal delivered another strong quarter, providing further evidence that our Amneal 2.0 strategy is positioning the company for sustained growth,” said Chirag and Chintu Patel, Co-Chief Executive Officers. “While the COVID pandemic continues to affect some aspects of the business, we continue to focus on execution, improving t

Amneal Reports Third Quarter 2020 Financial Results

Amneal (AMRX) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Should You Buy Amneal (AMRX) Ahead of Earnings?

Amneal (AMRX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Amneal Pharmaceuticals (AMRX) Reports Next Week: Wall Street Expects Earnings Growth

Amneal Pharmaceuticals (AMRX) closed at $4.36 in the latest trading session, marking a -1.13% move from the prior day.

Amneal Pharmaceuticals (AMRX) Stock Sinks As Market Gains: What You Should Know

Amneal (AMRX) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Why Amneal (AMRX) is Poised to Beat Earnings Estimates Again

Is (AMRX) Outperforming Other Medical Stocks This Year?

Is AMNEAL PHARMACEUTICALS, INC. (AMRX) Stock Outpacing Its Medical Peers This Year?

BRIDGEWATER, N.J.--(BUSINESS WIRE)--Amneal Pharmaceuticals, Inc. (NYSE: AMRX) announced today that the Company will release its third quarter 2020 financial results on Friday, November 6, 2020, prior to market open. The Company will host a conference call and live webcast with the investment community at 8:30 a.m. Eastern Time on November 6, 2020. The financial results and live webcast will be accessible through the Investor Relations section of the Company's website at https://investors.amneal

Amneal to Report Third Quarter 2020 Results on November 6, 2020

--(BUSINESS WIRE)--Amneal Pharmaceuticals, Inc. (NYSE:AMRX), headquartered in Bridgewater, NJ, is a fully-integrated pharmaceutical company focused on the development, manufacturing and distribution of generic and specialty drug products. The Company has operations in North America, Asia, and Europe, working together to bring high-quality medicines to patients primarily within the United States. Amneal has an extensive portfolio of approximately 250 product families and is expanding its portfol

Company Profile for Amneal Pharmaceuticals

BRIDGEWATER, N.J.--(BUSINESS WIRE)--Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (“Amneal’ or the “Company”) and PL Developments (PLD) today announced that they have commenced shipments of store brand equivalent Voltaren® Arthritis Pain Gel (diclofenac sodium topical gel, 1%) in 50, 100 and 150g laminate tubes following FDA clearance. Amneal and PLD have partnered to bring this important product to US retailers. Voltaren® Arthritis Pain was switched OTC in February of 2020, making it available to

Amneal & PL Developments Launch Store Brand Program of Over-the-Counter (“OTC”) Diclofenac Sodium Topical Gel, 1%

BRIDGEWATER, N.J.--(BUSINESS WIRE)--Amneal Pharmaceuticals, Inc.

Amneal to Virtually Participate at the Morgan Stanley Global Healthcare Conference

Amneal Receives Abbreviated New Drug Application Approval for Lidocaine Patch, 5%

Amneal Pharmaceuticals, Inc. (AMRX) CEO Chintu Patel on Q2 2020 Results - Earnings Call Transcript

Amneal Reports Second Quarter 2020 Financial Results

Amneal (AMRX) will provide financial updates when it reports second-quarter 2020 results.

Amneal (AMRX) to Report Q2 Earnings: What's in the Cards?

In the latest trading session, Amneal Pharmaceuticals (AMRX) closed at $4.46, marking a +0.45% move from the previous day.

Amneal Pharmaceuticals (AMRX) Gains As Market Dips: What You Should Know

Amneal Pharmaceuticals (AMRX) closed the most recent trading day at $4.86, moving +0.21% from the previous trading session.

News for Amneal Pharmaceuticals Stock (AMRX)